314 related articles for article (PubMed ID: 23826783)
21. [Treatment of familial amyloid polyneuropathy].
Adams D; Samuel D; Slama M
Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949
[TBL] [Abstract][Full Text] [Related]
22. [Familial amyloid polyneuropathy: clinicopathological aspects].
Koike H; Sobue G
Brain Nerve; 2014 Jul; 66(7):749-62. PubMed ID: 24998820
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic strategy for familial amyloid polyneuropathy (FAP)].
Ikeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):953-5. PubMed ID: 20030258
[TBL] [Abstract][Full Text] [Related]
24. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.
Sousa MM; Ferrão J; Fernandes R; Guimarães A; Geraldes JB; Perdigoto R; Tomé L; Mota O; Negrão L; Furtado AL; Saraiva MJ
Lab Invest; 2004 Jul; 84(7):865-73. PubMed ID: 15122304
[TBL] [Abstract][Full Text] [Related]
25. Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M).
de Carvalho M; Conceição I; Bentes C; Luís ML
Amyloid; 2002 Jun; 9(2):126-33. PubMed ID: 12440485
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
Ando Y
Amyloid; 2003 Aug; 10 Suppl 1():55-66. PubMed ID: 14640043
[TBL] [Abstract][Full Text] [Related]
27. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
Ferreira N; Saraiva MJ; Almeida MR
PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829
[TBL] [Abstract][Full Text] [Related]
28. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
[TBL] [Abstract][Full Text] [Related]
29. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.
Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ
Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349
[TBL] [Abstract][Full Text] [Related]
30. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
31. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Tojo K; Sekijima Y; Kelly JW; Ikeda S
Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
33. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.
Yazaki M; Liepnieks JJ; Kincaid JC; Benson MD
Muscle Nerve; 2003 Oct; 28(4):438-42. PubMed ID: 14506715
[TBL] [Abstract][Full Text] [Related]
34. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients.
Yazaki M; Mitsuhashi S; Tokuda T; Kametani F; Takei YI; Koyama J; Kawamorita A; Kanno H; Ikeda SI
Am J Transplant; 2007 Jan; 7(1):235-42. PubMed ID: 17061984
[TBL] [Abstract][Full Text] [Related]
35. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
36. Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Sekijima Y; Tokuda T; Kametani F; Tanaka K; Maruyama K; Ikeda S
Amyloid; 2001 Dec; 8(4):257-62. PubMed ID: 11791618
[TBL] [Abstract][Full Text] [Related]
37. Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.
Suenaga G; Ikeda T; Komohara Y; Takamatsu K; Kakuma T; Tasaki M; Misumi Y; Ueda M; Ito T; Senju S; Ando Y
PLoS One; 2016; 11(10):e0163944. PubMed ID: 27695122
[TBL] [Abstract][Full Text] [Related]
38. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration.
Hou X; Aguilar MI; Small DH
FEBS J; 2007 Apr; 274(7):1637-50. PubMed ID: 17381508
[TBL] [Abstract][Full Text] [Related]
39. [Ocular involvement in familial amyloid polyneuropathy].
Rousseau A; Kaswin G; Adams D; Cauquil C; Théaudin M; Mincheva Z; M'garrech M; Labetoulle M; Barreau E
J Fr Ophtalmol; 2013 Nov; 36(9):779-88. PubMed ID: 24144522
[TBL] [Abstract][Full Text] [Related]
40. Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study.
Mazzeo A; Toscano A; Stromillo ML; Battaglini M; Messina C; Federico A; Vita G; De Stefano N
J Neurol Sci; 2006 Jul; 246(1-2):31-5. PubMed ID: 16530227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
